Exhibit 10.18

AMAG PHARMACEUTICALS, INC.

RESTRICTED STOCK UNIT AWARD AGREEMENT

NON-PLAN INDUCEMENT GRANT

Name of Grantee:

 

 

No. of Restricted Stock Units:

 

 

 

Grant Date:

 

 

 

AMAG Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number
of Restricted Stock Units listed above (an “Award”) to the Grantee named above,
as an inducement grant made pursuant to Rule 5635(c)(4) of the NASDAQ Listing
Rules.  Each Restricted Stock Unit shall relate to one share of Common Stock,
par value $0.01 per share (the “Stock”) of the Company.  For the avoidance of
doubt, this Award is not issued under the Company’s Third Amended and Restated
2007 Equity Incentive Plan, as amended through the date hereof (the “Plan”) and
does not reduce the share reserve under the Plan.  However, for purposes of
interpreting the applicable provisions of this Award, the terms and conditions
of the Plan (other than those applicable to the share reserve) shall govern and
apply to this Award as if such Award had actually been issued under the Plan.

1.Restrictions on Transfer of Award.  This Award may not be sold, transferred,
pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any
shares of Stock issuable with respect to the Award may not be sold, transferred,
pledged, assigned or otherwise encumbered or disposed of until (i) the
Restricted Stock Units have vested as provided in Section 2 of this Agreement
and (ii) shares of Stock have been issued to the Grantee in accordance with the
terms of the Plan and this Agreement.

2.Vesting of Restricted Stock Units.  The restrictions and conditions of
Section 1 of this Agreement shall lapse on the Vesting Date or Dates specified
in the following schedule so long as the Grantee remains in a Business
Relationship (as defined in Section 3 below) on such Dates.  If a series of
Vesting Dates is specified, then the restrictions and conditions in Section 1
shall lapse only with respect to the number of Restricted Stock Units specified
as vested on such date.

Incremental Number of
Restricted Stock Units Vested

    

Vesting Date

 

 

 

_____________ (___%)

 

____________

_____________ (___%)

 

____________

_____________ (___%)

 

____________

The Administrator may at any time accelerate the vesting schedule specified in
this Section 2.

3.Termination of Business Relationship. 

(a)        If the Grantee’s Business Relationship terminates for any reason
(including death or disability) prior to the satisfaction of the vesting
conditions set forth in Section 2 above, any Restricted Stock Units that have
not vested as of such date shall automatically and without notice terminate and
be

Page 1 of 4

--------------------------------------------------------------------------------

 

forfeited, and neither the Grantee nor any of his or her successors, heirs,
assigns, or personal representatives will thereafter have any further rights or
interests in such unvested Restricted Stock Units.    

(b)        “Business Relationship” means service to the Company or any of its
Subsidiaries, or its or their successors, in the capacity of an employee,
officer, director, consultant or advisor.  For purposes hereof, a Business
Relationship shall not be considered as having terminated during any military
leave, sick leave, or other leave of absence if approved in writing by the
Company and if such written approval, or applicable law, contractually obligates
the Company to continue the Business Relationship of the Grantee after the
approved period of absence (an “Approved Leave of Absence”). In the event of an
Approved Leave of Absence, vesting of Restricted Stock Units shall be suspended
(and all subsequent vesting dates shall be postponed by the length of the period
of the Approved Leave of Absence) unless otherwise provided in the Company’s
written approval of the leave of absence. For purposes hereof, a Business
Relationship shall include a consulting arrangement between the Grantee and the
Company that immediately follows termination of employment, but only if so
stated in a written consulting agreement executed by the Company.

4.Issuance of Shares of Stock.  As soon as practicable following each Vesting
Date, the Company shall issue to the Grantee the number of shares of Stock equal
to the aggregate number of Restricted Stock Units that have vested pursuant to
Section 2 of this Agreement on such date and the Grantee shall thereafter have
all the rights of a stockholder of the Company with respect to such shares;
provided, however, if a Vesting Date shall occur during either a regularly
scheduled or special “blackout period” wherein the Grantee is precluded from
selling shares of Stock, the receipt of the corresponding underlying shares
issuable with respect to such Vesting Date pursuant to this Agreement shall be
deferred until after the expiration of such blackout period unless such
underlying shares are covered by a previously established Company-approved
10b5-1 plan of the Grantee, in which case the underlying shares shall be issued
in accordance with the terms of such 10b5-1 plan; provided, however, that the
issuance of such shares shall not be deferred any later than the later of: (a)
December 31st of the calendar year in which such vesting occurs, or (b) the 15th
day of the third calendar month following such vesting date, and if such
settlement occurs while either a regularly scheduled or special “blackout
period” is still in effect, neither the Company nor the Grantee may sell any
shares issued in settlement thereof to satisfy any tax or withholding
obligations except in compliance with the Company’s Statement of Company Policy
Regarding Insider Training and other applicable requirements and laws.

5.Incorporation of Plan.  As stated above, this Award is not granted pursuant to
the Plan.  Instead, this Award is granted as an inducement grant pursuant to
Rule 5635(c)(4) of the NASDAQ Listing Rules.  However, for purposes of
interpreting the application provisions of this Award, the terms and conditions
of the Plan (other than those applicable to the share reserve), including the
powers of the Administrator set forth in Section 2(b), shall govern and apply to
this Award as if such Award had actually been issued under the Plan. 
Capitalized terms in this Agreement shall have the meaning specified in the
Plan, unless a different meaning is specified herein.

6.Tax Withholding.  The Grantee shall, not later than the date as of which the
receipt of this Award becomes a taxable event for Federal income tax purposes,
pay to the Company or make arrangements satisfactory to the Company for payment
of any Federal, state, and local taxes required by law to be withheld on account
of such taxable event.  The Company shall have the authority to cause the
minimum required tax withholding obligation to be satisfied, in whole or in
part, by withholding from shares of Stock to be issued to the Grantee a number
of shares of Stock with an aggregate Fair Market Value that would satisfy the
minimum withholding amount due.

7.Section 409A of the Code.  This Agreement shall be interpreted in such a
manner that all provisions relating to the settlement of the Award are exempt
from the requirements of Section 409A of the Code as “short-term deferrals” as
described in Section 409A of the Code.

Page 2 of 4

--------------------------------------------------------------------------------

 

8.No Obligation to Continue Business Relationship.  Neither the Company nor any
Subsidiary is obligated by or as a result of the Plan or this Agreement to
continue the Grantee’s Business Relationship, and neither the Plan nor this
Agreement shall interfere in any way with the right of the Company or any
Subsidiary to terminate the Business Relationship of the Grantee at any time.

9.Integration.  This Agreement constitutes the entire agreement between the
parties with respect to this Award and supersedes all prior agreements and
discussions between the parties concerning such subject matter.

10.Data Privacy Consent.  In order to administer the Plan and this Agreement and
to implement or structure future equity grants, the Company, its subsidiaries
and affiliates and certain agents thereof (together, the “Relevant Companies”)
may process any and all personal or professional data, including but not limited
to Social Security or other identification number, home address and telephone
number, date of birth and other information that is necessary or desirable for
the administration of the Plan and/or this Agreement (the “Relevant
Information”).  By entering into this Agreement, the Grantee (i) authorizes the
Company to collect, process, register and transfer to the Relevant Companies all
Relevant Information; (ii) waives any privacy rights the Grantee may have with
respect to the Relevant Information; (iii) authorizes the Relevant Companies to
store and transmit such information in electronic form; and (iv) authorizes the
transfer of the Relevant Information to any jurisdiction in which the Relevant
Companies consider appropriate.  The Grantee shall have access to, and the right
to change, the Relevant Information.  Relevant Information will only be used in
accordance with applicable law.

11.Notices.  Notices hereunder shall be mailed or delivered to the Company at
its principal place of business to the attention of the Company’s Treasurer and
shall be mailed or delivered to the Grantee at the address on file with the
Company or, in either case, at such other address as one party may subsequently
furnish to the other party in writing.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

Page 3 of 4

--------------------------------------------------------------------------------

 

SIGNATURE PAGE TO AMAG PHARMACEUTICALS, INC.

RESTRICTED STOCK UNIT AWARD AGREEMENT

 

 

AMAG PHARMACEUTICALS, INC.

 

 

 

 

 

 

 

By:

 

 

 

Name:

William K. Heiden

 

 

Title:

Chief Executive Officer

The foregoing Agreement is hereby accepted and the terms and conditions thereof
hereby agreed to by the undersigned, and the undersigned acknowledges receipt of
a copy of this entire Agreement, a copy of the Plan, and a copy of the Plan’s
related prospectus.  Electronic acceptance of this Agreement pursuant to the
Company’s instructions to the Grantee (including through an online acceptance
process) is acceptable.

Dated:

 

 

 

 

 

 

Grantee’s Signature

 

 

 

 

 

 

 

 

 

 

 

Grantee’s name and address:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Page 4 of 4

--------------------------------------------------------------------------------